Datapoint: Elevance Adds Humira Biosimilars to Commercial Formularies

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
November 2

Elevance Health Inc.’s CarelonRx PBM will add two of Boehringer Ingelheim’s Humira biosimilars to some of its formularies starting Dec. 1, the firm said on Oct. 19. The move will put those drugs “at parity with Humira,” per a press release. The lower-list-price version of adalimumab-adbm  will be added to all CarelonRx’s commercial formularies, while Boehringer’s Cyltezo will be added to “select” commercial formularies, the press release added. Elevance currently covers 6.17 million commercial lives under the pharmacy benefit.

SOURCE: MMIT Analytics, as of 10/30/23

0
0 Comments
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
December 7

Datapoint: North Carolina Begins Medicaid Expansion Rollout

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
December 6

Datapoint: Clover Health to Exit ACO REACH Model

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
December 5

Datapoint: Aetna Will Keep Covering Some Virtual Behavioral Health Services

Read More

The Latest

enhance-patient-assistance-programs

Meet Our Reporters

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today